- Previous Close
2.3800 - Open
2.4500 - Bid 2.3900 x --
- Ask 2.4000 x --
- Day's Range
2.3700 - 2.4200 - 52 Week Range
1.6600 - 2.9900 - Volume
36,215,800 - Avg. Volume
62,058,401 - Market Cap (intraday)
5.367B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
59.75 - EPS (TTM)
0.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 28, 2019
- 1y Target Est
3.23
Harbin Gloria Pharmaceuticals Co., Ltd engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People's Republic of China.
www.gloria.cc3,085
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002437.SZ
View MorePerformance Overview: 002437.SZ
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002437.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002437.SZ
View MoreValuation Measures
Market Cap
5.37B
Enterprise Value
4.95B
Trailing P/E
65.48
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.16
Price/Book (mrq)
2.83
Enterprise Value/Revenue
2.03
Enterprise Value/EBITDA
31.82
Financial Highlights
Profitability and Income Statement
Profit Margin
3.30%
Return on Assets (ttm)
2.66%
Return on Equity (ttm)
4.74%
Revenue (ttm)
2.43B
Net Income Avi to Common (ttm)
80.2M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
468.71M
Total Debt/Equity (mrq)
2.52%
Levered Free Cash Flow (ttm)
230.55M